marimastat has been researched along with Disease Exacerbation in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (75.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Dharmasivam, M; Park, KC; Richardson, DR | 1 |
| Baryshnikov, A; Borovjagin, AV; Cobbs, C; Kaverina, N; Lin, B; Schroeder, B; Shah, N; Ulasov, I | 1 |
| Berger, M; Chang, S; Devriendt, D; Kunwar, S; Lamborn, KR; Larson, DA; McDermott, MW; Nicholas, KM; Prados, M; Smith, V; Sneed, PK; Wara, WM | 1 |
| Moses, MA; Pories, SE; Roy, R; Wewer, UM; Zurakowski, D | 1 |
| Didziapetriene, J; Kadziauskas, J; Stanciūte, D | 1 |
| Carducci, MA; DeWeese, TL; Eisenberger, MA; Laufer, M; Pili, R; Rosenbaum, E; Sinibaldi, V; Zahurak, M | 1 |
| Fingleton, B; Matrisian, LM; Nelson, AR; Rothenberg, ML | 1 |
| Baillet, M; Bramhall, SR; Brown, PD; Buckels, JA; Nemunaitis, J; Schulz, J | 1 |
2 review(s) available for marimastat and Disease Exacerbation
| Article | Year |
|---|---|
The Role of Extracellular Proteases in Tumor Progression and the Development of Innovative Metal Ion Chelators that Inhibit their Activity.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Transformation, Neoplastic; Chelating Agents; Disease Progression; Drug Design; Drug Screening Assays, Antitumor; Extracellular Fluid; Extracellular Vesicles; Humans; Hydroxamic Acids; Iron; Iron Chelating Agents; Kallikreins; Matrix Metalloproteinases; Molecular Targeted Therapy; Neoplasm Proteins; Oxaprozin; Peptide Hydrolases; Phenylalanine; Protease Inhibitors; Protein Kinases; Pyridines; Thiophenes; Thiosemicarbazones; Zinc | 2020 |
[Expression of matrix metalloproteinases in patients with malignant tumors].
Topics: Antineoplastic Agents; Apoptosis; Biphenyl Compounds; Clinical Trials as Topic; Diphosphonates; Disease Progression; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Humans; Hydroxamic Acids; Imidazoles; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Neoplasms; Organic Chemicals; Phenylalanine; Phenylbutyrates; Prognosis; Protease Inhibitors; Thiophenes; Time Factors; Tissue Inhibitor of Metalloproteinases | 2004 |
3 trial(s) available for marimastat and Disease Exacerbation
| Article | Year |
|---|---|
Phase II study of high central dose Gamma Knife radiosurgery and marimastat in patients with recurrent malignant glioma.
Topics: Adult; Aged; Brain Neoplasms; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Radiation; Enzyme Inhibitors; Female; Follow-Up Studies; Glioma; Humans; Hydroxamic Acids; Magnetic Resonance Imaging; Male; Middle Aged; Prospective Studies; Radiosurgery; Recurrence; Time Factors; Treatment Outcome | 2002 |
Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trial.
Topics: Aged; Analysis of Variance; Arthralgia; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Humans; Hydroxamic Acids; Male; Metalloendopeptidases; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Time; Treatment Outcome | 2005 |
A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Gemcitabine; Humans; Hydroxamic Acids; Life Tables; Male; Matrix Metalloproteinase Inhibitors; Middle Aged; Musculoskeletal Diseases; Neoplasm Proteins; Pancreatic Neoplasms; Protease Inhibitors; Quality of Life; Safety; Survival Analysis | 2002 |
3 other study(ies) available for marimastat and Disease Exacerbation
| Article | Year |
|---|---|
MT1-MMP silencing by an shRNA-armed glioma-targeted conditionally replicative adenovirus (CRAd) improves its anti-glioma efficacy in vitro and in vivo.
Topics: Adenoviridae; Aged; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Progression; Female; Gene Expression Regulation, Neoplastic; Genetic Therapy; Genetic Vectors; Glioma; Humans; Hydroxamic Acids; Interleukin-8; Male; Matrix Metalloproteinase 14; Mice; Middle Aged; Neoplasm Transplantation; Neovascularization, Pathologic; Oncolytic Virotherapy; RNA Interference; RNA, Small Interfering; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2015 |
ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage.
Topics: ADAM Proteins; ADAM12 Protein; Adult; Aged; Amino Acid Sequence; Animals; Blotting, Western; Breast Neoplasms; Caseins; Catalysis; Chelating Agents; Chromatography, Affinity; Chromatography, Ion Exchange; Collagen Type I; Collagen Type IV; COS Cells; Databases as Topic; Densitometry; Disease Progression; Edetic Acid; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; Extracellular Matrix; Female; Fibronectins; Gelatin; Humans; Hydroxamic Acids; Immunoblotting; Membrane Proteins; Metalloendopeptidases; Middle Aged; Molecular Sequence Data; Neoplasm Metastasis; Peptides; Phenanthrolines; Plasmids; Recombinant Proteins; Sensitivity and Specificity; Sepharose; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Substrate Specificity; Ultracentrifugation; Zinc | 2004 |
Matrix metalloproteinases: biologic activity and clinical implications.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Disease Models, Animal; Disease Progression; Enzyme Inhibitors; Humans; Hydroxamic Acids; Matrix Metalloproteinase 1; Matrix Metalloproteinase Inhibitors; Neoplasms; Organic Chemicals | 2000 |